NBIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Neurocrine Biosciences Inc (NBIX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and growth potential in its product pipeline outweigh the lack of immediate trading signals or recent news catalysts. Despite neutral technical indicators, the long-term growth outlook and analyst price targets suggest a favorable entry point.
The MACD histogram is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 49.37, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near a pivot level of 128.318, with resistance at 133.039 and support at 123.598. Overall, the technical indicators are mixed, with no strong trend direction.
Strong Q4 financial performance with revenue up 28.33% YoY, net income up 49.08% YoY, and EPS up 48.00% YoY.
Positive analyst sentiment with multiple Buy and Outperform ratings, and price targets ranging from $140 to $204, suggesting significant upside potential.
Encouraging growth outlook for key products like Ingrezza and Crenessity, with a robust pipeline.
Bearish moving averages and neutral RSI indicate no clear short-term upward momentum.
Lack of recent news or event-driven catalysts.
Neutral trading sentiment from hedge funds and insiders, with no significant activity in the last quarter.
In Q4 2025, Neurocrine reported revenue growth of 28.33% YoY to $805.5M, net income growth of 49.08% YoY to $153.7M, and EPS growth of 48.00% YoY to $1.48. Gross margin slightly declined by 0.71% YoY to 97.82%. Overall, the company demonstrated strong financial growth and profitability.
Analysts maintain a positive outlook on NBIX, with multiple Buy and Outperform ratings. Recent price target updates range from $140 to $204, reflecting confidence in the company's growth trajectory. Wolfe Research initiated coverage with an Outperform rating and a $160 price target, while JPMorgan and others see the current price as an attractive buying opportunity.
